184 related articles for article (PubMed ID: 16616004)
1. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
3. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
4. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
5. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
6. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
8. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Ryu S; Imai YN; Oiki S
Bioorg Med Chem Lett; 2013 Jul; 23(13):3848-51. PubMed ID: 23711922
[TBL] [Abstract][Full Text] [Related]
9. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
Moorthy NS; Ramos MJ; Fernandes PA
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
[TBL] [Abstract][Full Text] [Related]
10. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
12. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
Farid R; Day T; Friesner RA; Pearlstein RA
Bioorg Med Chem; 2006 May; 14(9):3160-73. PubMed ID: 16413785
[TBL] [Abstract][Full Text] [Related]
13. An automated docking protocol for hERG channel blockers.
Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
[TBL] [Abstract][Full Text] [Related]
14. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
[TBL] [Abstract][Full Text] [Related]
15. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
16. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
Moorthy NS; Ramos MJ; Fernandes PA
SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
[TBL] [Abstract][Full Text] [Related]
17. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
[TBL] [Abstract][Full Text] [Related]
18. The interactions between hERG potassium channel and blockers.
Du L; Li M; You Q
Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
[TBL] [Abstract][Full Text] [Related]
19. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
20. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]